EUVIMEDEUVIMED entdecken
Crossref

The Efficacy and Toxicity of Hypofractionated Regional Nodal Irradiation in Breast Cancer Patients

Daphna Y Spiegel, Julia Willcox, Josephine Levey, Laura E Dodge, Abram Recht

Practical Radiation Oncology · 2025

DOI: 10.1016/j.prro.2025.03.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Practical Radiation Oncology, 2025. Verfasst von Daphna Y Spiegel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Electronic address: dspiege…. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiation Dose Hypofractionation, Lymphatic Irradiation, Lymph Nodes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Center for Advancing Translational Sciences, National Institutes of Health, Harvard University Harvard Catalyst.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Regional nodal irradiation (RNI) is increasingly used in place of axillary lymph node dissection (ALND) in carefully selected breast cancer patients. Although hypofractioned whole breast irradiation is standard for node-negative disease, long-term data on hypofractionated RNI (HF-RNI) are limited. This study aims to assess the long-term safety and effectiveness of HF-RNI for breast cancer patients. METHODS AND MATERIALS: This retrospective analysis included 154 patients with node-positive or high-risk node-negative breast cancer treated with HF-RNI (>2 Gy/fraction) between 2008 and 2020. Median dose was 40 Gy/16 fractions to the breast, chest wall, or reconstructed breast as well as regional nodes. The primary endpoint was the incidence of chronic toxicity. Secondary endpoints were acute toxicity, local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), disease-free survival (DFS), and overall survival (OS). Acute toxicities were defined as those occurring during radiation therapy or within 90 days post-treatment; chronic toxicities were defined as those persisting or arising at least 180 days after radiation completion. RESULTS: Median follow-up was 65.4 months (range, 4-170 months). Median age was 58 years (interquartile range, 48.3-71.0). Sentinel lymph node biopsy was performed in 49.4% of patients, 47.4% underwent ALND, and 3.2% had no axillary surgery. RNI targets included supraclavicular and axillary level 1 to 3 nodes in 65.6% of patients, whereas 34.4% were treated only to the supraclavicular and level 3 nodes. There were 7 (4.7%) patients that had internal mammary nodes treated. Chronic brachial plexopathy occurred in 2.0% of patients, limited range of motion in 1.3%, and upper extremity lymphedema in 10.5%. Late cardiac and lung toxicity rates were low at 0.7% and 3.3%, respectively. Five-year actuarial rates of LRFS, RRFS, DFS, and OS were 98.0%, 99.3%, 90.1%, and 88.1%, respectively. CONCLUSIONS: HF-RNI demonstrates low rates of chronic toxicity and excellent disease control, supporting wider adoption in clinical practice. Long-term results of randomized trials of HF-RNI are needed for definitive evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRadiation Dose HypofractionationLymphatic IrradiationLymph NodesHumansFemaleMiddle AgedRetrospective StudiesAgedAdultLymphatic Metastasis

Autor:innen und Institutionen

  • Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Electronic address: dspiege1@bidmc.harvard.edu.
  • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachuset…
  • Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.

Förderung

  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • Harvard University Harvard Catalyst
  • Harvard University
  • National Center for Research Resources

Zitieren

APA

Spiegel, D. Y., Willcox, J., Levey, J., Dodge, L. E., & Recht, A. (2025). The Efficacy and Toxicity of Hypofractionated Regional Nodal Irradiation in Breast Cancer Patients. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2025.03.014

Vancouver

Spiegel DY, Willcox J, Levey J, Dodge LE, Recht A. The Efficacy and Toxicity of Hypofractionated Regional Nodal Irradiation in Breast Cancer Patients. Practical Radiation Oncology. 2025. doi:10.1016/j.prro.2025.03.014

BibTeX
@article{Spiegel2025,
  author = {Spiegel, Daphna Y and Willcox, Julia and Levey, Josephine and Dodge, Laura E and Recht, Abram},
  title = {The Efficacy and Toxicity of Hypofractionated Regional Nodal Irradiation in Breast Cancer Patients},
  journal = {Practical Radiation Oncology},
  year = {2025},
  doi = {10.1016/j.prro.2025.03.014}
}
Kostenlos starten →